Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $51.25M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.26pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 45.5¢ | Day High | 48.0¢ | Day Low | 45.5¢ | |||
| Daily Volume | 192306 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 44.5¢ | 9299 | 0 | 50.0¢ | 45318 | |
Directors & Senior Management
| Ms. Anastasia Tan | Head of Operations & Supply Chain |
| Ms. Anita James | Chief Financial Officer |
| Mr. Anthony Wheal | Head of People & Culture |
| Mr. Benson Lee | Head of Commercial Operations |
| Mr. Brent MacGregor | Chief Executive Officer |
| Ms. Christine Emmanuel-Donnelly | Non-Executive Director |
| Ms. Julianne Alexander | Head of Medical Affairs, Regulatory Affairs & Clinical Development |
| Mr. Leon G. Hoare | Non-Executive Director |
| Mr. Mark Donald Fladrich | Chair of the Board |
| Mr. Paul Ronald Townsend | Deputy Chair |
| Dr. Russell Basser | Non-Executive Director |
| Dr. Scott Courtney | Chief Scientific Officer |
| Ms. Tara Eaton | General Counsel & Company Secretary |
| Wayne Pearce | Head of Production |
Data source: ADVFN
